Purpose: To report the 1-year functional outcomes, oncologic outcomes, and postoperative complications in patients who underwent modified robot-assisted radical prostatectomy (RARP) procedures for achieving early recovery of continence and potency postoperatively. Materials and Methods: This study included 165 patients who underwent RARP. Overall, 98 patients underwent RARP using our modified detrusorrhaphy and intrafascial nerve-sparing techniques (group 1) and 67 underwent standard RARP (group 2). Continence and potency rates were assessed at 1 week, 1, 3, 6, and 12 months after RARP. Oncologic outcomes comprised positive surgical margins (PSMs) and biochemical recurrence (BCR) rate. Results: The continence rates were 61. 2% and 6. 0%, 72. 5% and 11. 9%, 79. 6% and 20. 9%, 91. 8% and 58. 2%, and 97. 9% and 74. 6% at 1 week, 1, 3, 6, and 12 months in group 1 and 2, respectively. The potency rates were 66. 3% and 11. 9%, 78. 6% and 38. 8%, 85. 7% and 50. 8%, 92. 9% and 70. 2%, and 95. 9% and 79. 1% at 1 week, 1, 3, 6, and 12 months in group 1 and 2, respectively. Overall postoperative complication rates (< 10%) were similar between the groups. The PSMs rate was 17. 4% and 16. 4% in the two groups. The rate of PSMs in the cohort of patients with stage pT2 disease decreased to 13. 6% and 12. 5% in groups 1 and 2, respectively. BCR rate was 5. 1% and 6. 0% in groups 1 and 2, respectively. Conclusion: The use of detrusorrhaphy and intrafascial nerve-sparing techniques is safe and feasible, with our results demonstrating early return to continence and potency. Further studies should be conducted.